Over the past few years, large scale genomics projects such as the ENCODE and Roadmap Epigenomics have produced genome-wide data on a large number of biochemical assays for a diverse set of human cell types and tissues. Such data play an important role in predicting the functional effects of noncoding genetic variation. We discuss here unsupervised approaches to integrate these diverse annotations for specific tissues and cell types into a single predictor of tissue-specific functional importance. We provide a global view of the sharing of functional variants across large number of tissues and cell types, and demonstrate that functional variants in promoters are more likely to be shared across many tissues compared with enhancers. A multidimensional scaling analysis based on functional scores in multiple tissues reveals clear patterns of similarity between certain tissue types, including similarity between primary tissues derived from the same embryonic tissue of origin. Using eQTL data from the Genotype-Tissue Expression (GTEx) project we show that eQTLs in specific GTEx tissues tend to be most enriched among the functional variants in relevant tissues in Roadmap. Furthermore, we show how these integrated functional scores can be used to derive the most likely tissue-/cell-type for a complex trait using summary statistics from genome-wide association studies (GWAS), and derive a tissue-based correlation map of various complex traits. Finally, we show how the tissue-specific functional scores in conjunction with GWAS summary statistics can shed light on genes and biological processes implicated in a complex trait. Functional scores are available for every possible position in the hg19 human reference genome for 127 tissues and cell types assayed in Roadmap Epigenomics.
Introduction
Understanding the functional consequences of noncoding genetic variation is one of the most important problems in human genetics. Comparative genomics studies suggest that most of the mammalian conserved and recently adapted regions consist of noncoding elements [1, 2, 3] . Furthermore, most of the loci identified in genome-wide association studies fall in noncoding regions [4] and are likely to be involved in gene regulation in a tissue-and cell-type specific manner. Noncoding variants are also known to play an important role in cancer. Somatic variants in noncoding regions can act as drivers of tumor progression and germline noncoding variants can act as risk alleles [5] . Thus, improved understanding of tissue-specific functional effects of noncoding variants will have implications for multiple diseases and traits.
Prediction of the functional effects of genetic variation is difficult for several reasons. To begin with, there is no single definition of function. As discussed in [6] there are several possible definitions, depending on whether one considers genetic, evolutionary conservation or biochemical perspectives. These different approaches each have limitations and vary substantially with respect to the specific regions of the human genome that they predict to be functional. In particular, the genetic approach, based on evaluating the phenotypic consequence of a sequence alteration, tends to have low throughput and may miss elements that lead to phenotypic effects manifest only in rare cells or specific environmental contexts. The evolutionary approach relies on accurate multispecies alignment which makes it challenging to identify certain functional elements, such as distal regulatory elements, although recently several approaches have been developed for primate-or even human-specific elements [7] . Another limitation of the evolutionary approach is that it is not sensitive to tissue-and cell-type. Finally, the biochemical approach, although helpful in identifying potentially regulatory elements in specific contexts, does not provide definitive proof of function since the observed biochemical signatures can occur stochastically. Another main difficulty for computational methods is the lack of gold-standard labeled data, especially in a tissue-and celltype specific manner, that could be used as training examples in supervised learning [8] . We have previously shown that unsupervised approaches can perform well in this setting [9] . The approach in [9] , like other functional prediction tools such as CADD [10] and FunSeq [2, 11] , are not specific to particular tissues or cell types.
Here we are interested in predicting functional effects of genetic variants in a particular tissueor cell-type. The ENCODE Project [3] and the NIH Roadmap Epigenomics Program [12] have profiled various epigenetic features in more than 100 different tissues and cell types (Supplemental Tables S1 and S2 ). We use the Roadmap tissue-specific resource to predict the functional effects of genetic variants in a tissue-specific manner. Most of the epigenetic features profiled by Roadmap are histone modifications, and we focus on these marks here. Histone modifications are chemical modifications of the DNA-binding histone proteins that influence transcription as well as other DNA processes. Particular histone modifications have characteristic genomic distributions [13] . For example, trimethylation of histone H3 at lysine 4 (H3K4me3) is associated with promoter regions, monomethylation at H3K4 (H3K4me1) is associated with enhancer regions, and acetylation of H3K27 (H3K27ac) and of H3K9 (H3K9ac) are associated with increased activation of enhancer and promoter regions, respectively [12] . There are dozens of chromatin marks assayed in large numbers of different tissues and cell types, and studying them individually is inefficient. Trynka et al. [14] have shown that the most phenotypically cell-type specific chromatin marks are H3K4me3, along with H3K4me1, and H3K9ac; in particular they report H3K4me3 as the mark most phenotypically cell-type specific. We focus here on four of these most informative marks, namely H3K4me3, H3K4me1, H3K9ac, and H3K27ac. We introduce an integrated functional score that combines these different epigenetic chromatin marks in specific tissues and cell types. We present results from a flexible nonparametric mixture model, assuming that the variants can be partitioned into two groups, functional and nonfunctional in a particular tissue, and modeling the multivariate annotation data using two-component mixture models, with components corresponding to the two groups.
Here we (1) provide tissue-and cell-type specific functional scores for every possible position in the hg19 human genome for 127 tissues and cell types in Roadmap, (2) provide a global view of the sharing of functional variants across large number of tissues and cell types, and demonstrate that functional variants in promoters are more likely to be shared across many tissues as compared with enhancers, (3) show that eQTLs identified in a specific GTEx tissue tend to be most enriched among the functional variants in a relevant Roadmap tissue, (4) use these tissue-and cell-type specific scores in conjunction with summary statistics from 21 genome-wide association studies (GWAS) to identify the most likely causal tissue-/cell-type for a particular trait, and build a tissue-based correlation matrix among these complex traits, and (5) use tissue-specific functional variants and GWAS summary statistics to identify genes and biological processes important to complex traits.
Results

2.1.
Tissue-and cell-type specific scores. Here we use data for the histone modification marks H3K4me1, H3K4me3, H3K9ac, and H3K27ac for 127 different tissue-and cell-types represented in the Roadmap datasets (see Supplemental Tables S1 and S2 ; see also Supplemental Material and Supplemental Figure S1 for more information on these four annotations). Not all of these marks were profiled for each of the 127 different cell types and tissues. However, using the relationships between different marks within and across tissues, signal tracks have been predicted for each of these marks across all tissues [12] . We make use of these predicted signal tracks to compute integrated scores for every possible variant in the human sequence, for 127 cell types and tissues. Figure  1(B) ), blood cells continue to co-cluster and separate from solid tissues in the first dimension, but the second dimension becomes reflective of the embryonic tissue of origin. Along this dimension, the tissues follow the approximate order from ectoderm-derived, mesoderm-derived, to endodermderived, suggesting that epigenetic marks are more similar in tissues of the same embryonic origin. These results also indicate that ectoderm-and endoderm-derived tissues are most distant from each other, while mesoderm-derived tissues are more likely to share regulatory elements with ectodermand endoderm-derived tissue types.
In Figure 2 we provide a global picture of the sharing of functional variants across tissues in Roadmap, using the generalized Jaccard similarity index, a measure of overlap between functional variants in two tissues (see Methods). As shown there is generally low overlap between functional variants in different tissues, especially those in blood and other tissues. Overall, the median Jaccard index across all pairs of tissues is 0.37. As a comparison, we have computed these overlap indices using only functional variants that fall in promoters (Methods; Supplemental Figure S2 ) and enhancers (Methods; Supplemental Figure S3 ). The median Jaccard index for variants falling in promoters is 0.42, and 0.22 for variants falling in enhancers, concordant with the expectation that there is more sharing across tissues for functional variants in the promoters vs. those in enhancers. The patterns of sharing vary across pairs of tissues. For example, the median Jaccard index for the overlap between any blood tissue and the rest of the tissues is 0.32; 0.17 when considering only variants that fall in enhancers, and 0.37 for variants that fall in promoters. Also, concordant with recent analyses [16] investigating the overlap among eQTLs across four tissues (skin, fat, whole blood and lymphoblastoid cell lines), we find considerable overlap of functional variants in fat and skin tissues. For example, the Jaccard index of overlap between functional variants in 'Adipose Derived Mesenchymal Stem Cells' and functional variants in 'Foreskin Fibroblast Primary Cells' is 0.61; 0.66 when considering only variants that fall in promoters, and 0.62 for variants in enhancers. These overlap indices for fat and skin tissues are substantially higher than the median overlap among the tissues in Roadmap, as described above. Because of limitations in sample sizes, most existing studies, including GTEx, focus on the detection of cis-eQTLs, and are able to show a high degree of eQTL sharing across tissues. However, most of the genetic variants that contribute to the heritability of gene expression remain to be identified, and variance-component methods point to limited sharing of trans effects [16] , concordant with our empirical findings using functional variants across the entire genome.
Similarly, we show in Figure 3 the distribution of composite functional score (summed across all 127 tissues) for common variants in the 1000 Genomes data, only for variants in promoters, and only for variants in enhancers. As shown before in studies using cis-eQTLs identified in the GTEx project [17] , this distribution is bimodal for variants that fall in promoters, showing a group of SNPs functional across all tissues. In contrast, variants that fall in enhancers show a distribution skewed towards less sharing across all tissues, but rather sharing between a few tissues.
2.2. Enrichment analyses using eQTLs from the Genotype-Tissue Expression project. The Genotype-Tissue Expression (GTEx) project is designed to establish a comprehensive data resource on genetic variation, gene expression and other molecular phenotypes across multiple human tissues [17] . We focus here on the cis-eQTL results from the GTEx V6 release comprising RNA-seq data on 7051 samples in 44 tissues, each with at least 70 samples (Supplemental Table  S3 ). We are interested in identifying for each GTEx tissue the Roadmap tissues that are most enriched in eQTLs from that GTEx tissue relative to other GTEx tissues (see Methods). In Table  1 we show the top Roadmap Tissue for each GTEx tissue. In most cases, eQTLs from a GTEx tissue show the most enrichment in the functional component of a relevant Roadmap tissue. For example, for the liver tissue in GTEx, liver is the Roadmap tissue with the highest enrichment, for the pancreas tissue in GTEx, the Roadmap tissue with the highest enrichment is pancreas. However, there are also some cases where the top tissue is not necessarily the most intuitive one, and this is especially apparent for tissues of male and female reproductive system. This may be due to small sample sizes for eQTL discovery in GTEx for these tissues (only one sex is contributing). Additionally, some GTEx tissues with unexpected pairings do not have representative counterparts in Roadmap (e.g. thyroid, peripheral nerve, testis, and prostate). Nevertheless, most tissues that are analyzed by GTEx in sufficient numbers can be paired precisely with their existing Roadmap counterparts using our simple enrichment test.
2.3. Prediction of causal tissues for 21 complex traits. As an application of our scores to complex trait genetics, we use the recently-developed LD score regression framework [18] to identify the most relevant tissues and cell types for 21 complex traits for which moderate to large GWAS studies have been performed (Table 2; [19]- [39] ). The stratified LD score regression approach uses information from all SNPs and explicitly models linkage disequilibrium (LD) to estimate the contribution to heritability of different functional elements. We modify this method to weight SNPs by their tissue specific functional score, and in this way we assess the contribution to heritability of functional SNPs in a particular Roadmap tissue-or cell-type (see Supplemental Material for more details).
In Table 2 we show the top Roadmap tissue-/cell-type for each of the 21 complex traits. For most disorders, the top tissue has previously been implicated in their pathogenesis. Notably, recent data indicates that BMI-associated loci are enriched for expression in the brain and central nervous system [40] . Consistent with these findings, our analysis points to the highest tissue association of BMI with cells of the Brain Germinal Matrix. Similarly, brain represents the top tissue for most neuropsychiatric disorders, education levels, age at menarche and smoking. Blood-derived and immune cells represent the top tissue for virtually all of the autoimmune conditions available for analysis. For example, GWAS findings for ulcerative colitis and Crohn's disease both map specifically to the regulatory elements in Th17 cells, whereas lymphoblastoid cell lines represent the top cell type for IgA nephropathy and rheumatoid arthritis. The most unexpected findings include small intestine as the top tissue for coronary artery disease, primary hematopoietic stem cells for Alzheimer's disease (although bone marrow-derived hematopoietic stem cell therapy has been previously explored in Alzheimer's disease [41] ), and CD14+ monocytes for bipolar disorder.
In Figure 4 we show the correlation matrix for the 21 traits based on the Z-scores from the LD score regressions. This correlation structure reflects the extent to which traits share the same causal tissues, rather than the genetic correlation [42] . Three large phenotypic clusters are clearly evident. The most tightly correlated cluster contains autoimmune and inflammatory conditions, including inflammatory bowel diseases, alopecia areata, rheumatoid arthritis and IgA nephropathy. As expected, these conditions share highest functional scores in blood-derived immune cells. The second most strongly inter-correlated cluster is driven by scores in neuronal tissues, and consists of BMI, age at menarche, educational attainment, schizophrenia, and smoking history, with somewhat weaker correlations with epilepsy and bipolar disorder. Lastly, there is a clear co-clustering of cardio-metabolic traits that map to the tissues of liver, pancreas, and small intestine. Interestingly, height, coronary artery disease, and type 2 diabetes all share high functional scores in similar tissues, but are negatively correlated with autoimmune and neuronal disease clusters, suggesting a distinct set of tissues and regulatory elements that are specific to these traits.
2.4.
Gene-based analyses using tissue specific functional SNPs and enhancers-target genes maps. We have applied a Bayesian gene-based test to assess the association between individual genes and each of the 21 complex traits. Specifically, we first identified for each trait the variants predicted to be functional in the top tissue in Table 2 (namely those variants with posterior probability to be in the functional class greater than 0.5). This reduces the number of variants considered for each trait considerably (on average about 7.7% of variants are retained). For each gene we then included all the functional variants assigned to the gene (see Methods; see also Supplemental Table S4 for a breakdown of variants into different positional classes). We computed for each gene a Bayes factor (BF; Methods).
In Figure 5 we show for each of the 21 complex traits the log(BF) for those genes with log(BF)> 0, namely those genes with positive support of an association with trait. Of these genes, those with log(BF)> 5 provide very strong evidence of an association. As shown, highly polygenic traits, such as schizophrenia and height, have the largest number of genes with log(BF)> 5 (namely, 74 for schizophrenia and 118 for height). Similarly LDL, HDL, triglycerides, inflammatory bowel disease and rheumatoid arthritis have large number of genes (57 − 92) with large BFs, followed by age at menarche with 49 genes, alopecia areata with 33 genes and Alzheimer's disease with 27 genes. Because of small sample sizes for autism and epilepsy GWAS, these diseases have the weakest genebased associations results. We provide genes ranked based on their corresponding log(BF) for each of the 21 traits in the Supplemental Material.
We next tested whether the genes with log(BF)> 0, i.e. those showing positive support for association with the trait, are enriched in specific KEGG pathways by GSEA [43] (see Methods). All significant (FDR< 5%) KEGG pathways for these traits are listed in the Supplemental Material. This analysis replicates several previously reported pathway associations. For example, for height we recapitulate previously reported enrichment for "Pathways in Cancer", "TGF-beta Signaling", and "WNT Signaling" [44] . For IgAN, we confirm highly significant enrichment for the pathways of "Intestinal Immune Network for IgA Production" and "Leishmania Infection" [35] . Similarly, the top most significant pathways common for IBD include previously implicated "JAK-STAT Signaling Pathway", "Chemokine Signaling Pathway", and "Cytokine-Cytokine Receptor Interaction" [26] . For alopecia areata, there is extensive overlap with the results from a previous pathway analysis of GWAS loci, including the identification of immune pathways and known disease comorbidities [27] . Most notably, our analysis placed "JAK-STAT signaling" among the most significant pathways, which has high clinical relevance due to our work validating etiological contributions with immunological and pharmacological studies in the mouse model and human patients [28] . For Alzheimer's Disease we found significant enrichments in several immune pathways for Alzheimer's Disease, including "Systemic Lupus Erythematosus", "Asthma", and "Allograft Rejection", confirming previous findings about a role for immune response and inflammation genes in Alzheimer's Disease [29] .
Among novel findings, we observed "TGF-beta Signaling Pathway" enrichment for Type 2 Diabetes (P = 4.8 × 10 −7 ); and enrichments in the pathways of "Axon Guidance" (P = 4.2 × 10 −6 ), "MAPK Signaling" (P = 8.8 × 10 −6 ), and "Fc-gamma Receptor Mediated Phogocytosis" (P = 9.7 × 10 −6 ) for Age at Menarche. In addition, we observed "KEGG Lysosome" pathway enrichment for Coronary Artery Disease (P = 8.9 × 10 −5 ); "Adherens Junctions" (P = 6.7 × 10 −5 ), "Proteosome" (P = 1.6 × 10 −4 ), and "Glycerolipid Metabolism" (P = 1.7 × 10 −4 ) for HDL; and "Complement and Coagulation Cascade" (P = 1.0 × 10 −5 ) for triglycerides levels. These findings provide several novel insights into disease-associated biological processes and generate new hypotheses and can be tested in focused experimental studies. Moreover, our results demonstrate that the information on tissue-specific functional variants combined with GWAS summary statistics can be used effectively to identify candidate disease genes and highlight specific pathogenic pathways for complex traits.
Discussion
We have presented here an unsupervised approach for the functional prediction of genetic variation in specific tissue-/cell-types using histone modification data from the Roadmap Epigenomics project. Such context specific functional prediction of genetic variation is essential for the interpretation of genetic variants implicated by GWAS of complex traits. Although one could use individual tissue-and cell-type specific histone marks, the large number of such epigenetic markers and the large number of tissue-and cell-types make the individual analysis of these features inefficient, and the resulting results difficult to interpret. Therefore we have proposed here an integrated functional score.
Our approach is nonparametric, and as such is very flexible and can accommodate any type of continuous distributions. We note that since the histone modifications we consider in our applications can be dichotomized, for example, with peak calling methods [46] , alternative parametric methods are also possible [47] . In the Methods section and the Supplement we also consider two parametric approaches based on mixtures of multivariate Bernoulli distributions. As shown, these parametric methods perform similarly to our nonparametric approach. The parametric approaches, although simple, lack flexibility and require the data to be dichotomized (more generally, conform to a parametric distribution). As discussed in [48] , chromatin immunoprecipitation sequencing (ChIP-seq) experiments targeting histone modifications require difficult experimental conditions, and as such the resulting data quality can be low, especially in low input samples, making the conversion to dichotomous variables problematic.
We show that the overlap of functional variants across tissues shows an almost block diagonal structure, with fairly large overlap among closely related tissues and low overlap among different types of tissues. As shown before in the context of eQTL studies, functional variants in blood have the least overlap with functional variants in other tissues. Furthermore we show that functional variants in enhancer elements are less likely to be shared across many tissues, compared with functional variants in promoters. Our results on the overlap of functional variants across tissues can be used to select a surrogate tissue for a trait of interest when data on the true tissue is not available.
Tissue-and cell-type specific scores have important applications to complex trait genetics. As shown before [18], they can be used to infer the most relevant tissue for a trait of interest, and can help focus the search for causal variants in complex traits by restricting the set of candidate variants to only those that are predicted to be functional in a tissue relevant for the trait.
These context specific scores can also be used in improving power of eQTL studies, especially when testing large number of trans-eQTLs-gene pairs. Due to the very large number of possible SNP-gene pairs, trans-eQTL studies have had limited success so far, especially with modest sample sizes available at this time in projects such as GTEx. In such cases, using the tissue specific functional scores as prior information in a weighted-FDR framework can be helpful.
Related methods such as ChromHMM [49] and Segway [50] differ in important ways from our approach. While such methods integrate multiple chromatin datasets just as our own method, their goal is to segment the genome into non-overlapping segments, representing major patterns of chromatin marks, and label these segments using a small set of labels such as transcription start site, promoter flanking, enhancer etc.. Our approach aims to provide variant resolution functional predictions across multiple tissues and cell types, recognizing that not all variants falling into a functional segment have the same functional effect. For the 127 different tissues and cell types, our approach labels on average 4% of the genome as functional in a specific tissue or cell type, while ChromHMM and Segway tend to label a larger proportion of variants sitting in functional segments.
The accuracy of the results presented in this work is dependent on having sufficiently large sample sizes for the GWAS studies, and biochemical assays for a comprehensive set of tissues and cell types. This is especially true for identifying specific genes associated with traits of interest. Our results on pinpointing genes with strong evidence for association with a trait mirror results from GWAS studies, with traits such as schizophrenia and height showing large numbers of strong associations, while autism and epilepsy resulting in no strong candidates due to small sample sizes for the corresponding GWAS studies.
Precomputed scores for every possible variant in the human genome, for 127 tissue-and cell-types available in Roadmap are available for download at our website. 
. . , Z m ) be the set of functional scores for all the variants. We assume all the scores are continuous. We assume there exists an underlying two-component mixture model, corresponding to two possible functional classes for the variants: functional and non-functional. We also let C = (C 1 , . . . , C m ) denote the set of indicator variables for all the variants, where C i = 1 if variant i is functional and C i = 0 if variant i is non-functional. We are not able to observe C. Our primary goal here is to fit a nonparametric mixture model ψ with two components: ψ = (π, f 0 , f 1 ), where f 0 and f 1 are the probability densities for each of the components and π is a mixing parameter, and to calculate posterior probabilities for each variant to be functional given the observed scores Z, i.e. P ψ (C i = 1|Z).
We use an EM-like algorithm and a kernel method for the nonparametric density estimation of the component densities in the mixture model. This algorithm is similar to that described in [51] for fitting nonparametric multivariate mixtures; however whereas they assume the individual scores to be conditionally independent, we relax the assumption and only require blockwise conditional independence, and scores within a block having arbitrary distributions and correlation structures.
Let B be the number of conditionally independent blocks, containing n 1 , . . . , n B annotations respectively. The observations are then contained in R n 1 × R n 2 × · · · × R n B = R k . Because of the assumption of conditional independence among scores in different blocks, for any u = (u 1 , . . . , u k ) we can write:
f 0j (ũ j ), and
where f 0j and f 1j are multivariate densities corresponding to scores in block j, continuous on R n j . Also,ũ j corresponds to the scores in the jth block.
We propose the following EM-like algorithm for the nonparametric estimation of the mixture model ψ = (π, f 0 , f 1 ):
Step 1. Use k-means clustering to obtain initial component membership probabilities, i.e. initialize the posterior probability p i to be 1 for each variant i in the functional group and 0 for the variants in the non-functional group.
Step 2. Fit a multivariate kernel density estimate for each block and component separately:
and f new 0j
for each block j = 1 . . . B, weighting variants by component membership probability. More explicitly, for any u = (ũ 1 , . . . ,ũ B ) ∈ R k and j = 1, . . . , B, we let
For each block j, we take both H 0j and H 1j to be the same. The kernel is taken to be the probability density function of M V N (0, H), where H = diag(h 1 , . . . , h k ) is a diagonal bandwidth matrix (hence a product kernel). We choose the bandwidth parameter h i to be
according to a rule of thumb due to Silverman [52] , where SD i and IQR i are the standard deviation and interquartile range of score i, respectively. Choosing an appropriate bandwidth is very important for the accuracy of the estimation. The bandwidth we chose will work well if the true density resembles the normal distribution, but can be quite misleading when the true density deviates from the normal distribution (e.g. for multimodal distributions).
Step 3. Update component membership probabilities based on the fitted densities. Given current
), update the posterior probability for each variant i to be functional given the scores, i.e. P ψ (C i = 1 | Z), where i = 1, . . . , m, by
.
Repeat Steps 2-3 until convergence criterium is met.
We refer to this approach as the nonparametric (multivariate) mixture model with block structure. 4.1.2. Nonparametric (multivariate) mixture model with conditional independence assumptions. We also consider a particular model that assumes conditional independence among annotations, i.e., that ignores the block structure mentioned above. By taking the bandwidth matrix H in the multivariate mixture model to be H = diag(h 1 , . . . , h k ), where h i is specified according to the Silverman's rule, and assuming each annotation is in its own block, we get a multivariate mixture model with a conditional independence covariance structure. This is the same npEM model as in [51] , and is implemented in the R package mixtools [53] .
We fit two different npEM models using annotation data from two different sets of variants. For one npEM model, we use all the variants whose posterior probabilities we wish to calculate. Since the kernel density estimation step implemented in the R package mixtools is too slow for use with millions of variants, for this model we replace that step with a binned kernel density estimation using the R package KernSmooth [54] . This method is based on a regular grid with equally spaced points at which the density is estimated. We call this method npEM-binned. For the other npEM model, we use a different method to select a set of 20, 000 variants to use to train the npEM model for each tissue, with overrepresentation of variants with low and high functional annotation scores. For each functional annotation (in practice we use k = 4 functional annotations), we randomly select 2, 500 variants equally distributed among the following quantiles of the functional annotation scores for all variants for that annotation: 0, 0.00001, 0.0001, 0.001, 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 0.99, 0.999, 0.9999, 0.99999. We then randomly select enough additional variants so that we have 20, 000 variants in our training set. We then use this training set to train a different npEM model for each tissue. We can then use these models to calculate tissue-specific posterior probabilities for any variant (even one not in the training set), using our estimates of the component-specific densities f 0 and f 1 and the mixing parameter π. We call this method npEMquantile. The results in the Results section are those from the npEM-quantile method, since, as we show in the Supplemental Material, this method is robust and tends to perform well relative to alternative approaches we considered. 4.1.3. Identifiability issues. Nonparametric mixture models are not identifiable in general. However, under certain conditions nonparametric mixtures are identifiable. This has been shown to be the case for multivariate mixtures with two components in R k for k ≥ 3, if the coordinates are conditionally independent given the component [55] . In particular, the nonparametric mixture model with conditional independence is identifiable as long as there are at least 3 annotations. This result generalizes to the setting of blockwise conditional independence, as long as there are at least three blocks that are independent, conditionally on the latent functional class [56] .
4.1.4. Convergence issues. Nonparametric density estimation in high dimensions is challenging. Kernel density estimation, as used here, works well for small dimensions (e.g. d ≤ 3). For dimension d, the best bandwidth selection method leads to a mean integrated squared error of O(m −4/(4+d) ) [54] , which grows very slowly with m as d increases. In this paper we use blocks of small dimension (max d is 4). When d = 4, the best convergence rate is O(m −0.5 ). Hence, at this rate, to reduce estimation error in half, one would need a four-fold increase in the size (i.e. number of variants) of the dataset.
Eigen-PC.
A related approach for integrating the different annotations for a genetic variant has been introduced in Ionita-Laza et al. [9] . The underlying model is also a two component nonparametric mixture model. This approach is based on the eigendecomposition of the annotation covariance matrix, and using the lead eigenvector to weight the individual annotations. More precisely, if we denote by Q the variance-covariance matrix of the annotation scores Z, we take the eigendecomposition of Q, and the score for a variant is the weighted sum of the annotations, with the vector of weights equal to the first eigenvector of Q. We have shown in [9] that the Eigen-PC score performs favorably against existing methods such as CADD [10] , especially for noncoding variants.
4.1.6. Parametric (multivariate Bernoulli) mixture models. In our particular application to histone modification data from Roadmap Epigenomics, it is possible to discretize the data since in theory a histone modification is either present or absent at a specific genomic position (we make use of the results of gapped peak calling on the signal tracks). Using the same notations as before, we now assume the k annotations for a variant, Z i = (Z i1 , . . . , Z ik ), are binary. The simplest model (mvB) assumes conditional independence among all k annotations. This model is similar to the one in [47] .
Let p 1 = (p 11 , . . . , p 1k ) and p 0 = (p 01 , . . . , p 0k ). Then the EM algorithm for estimating the mixture of multivariate Bernoulli model ψ = (π, p 1 , p 0 ) is as follows:
Step 1. Use k-means clustering to obtain initial estimates for the parameters.
Step 2.
where p j = (p j1 , . . . , p jk ) for j = 0, 1. Repeat Steps 2-3 until convergence criterium is met.
4.1.7. Identifiability issues. It is well known that finite mixtures of Bernoulli products are not identifiable in a strict sense [57] . However, Allman et al. [56] have shown that finite mixtures of Bernoulli products are in fact generically identifiable, which means that only a subset of parameters of measure zero may not be identifiable. In other words, any observed dataset has probability one of being drawn from a distribution with identifiable parameters. This explains why in practice it makes sense to estimate these models, despite their lack of strict identifiability. Allman et al. [56] show that an r component mixture of products of p independent Bernoulli is generically identifiable if p ≥ 2 log 2 (r) + 1. In our case, since we assume r = 2 we need to have at least 3 independent Bernoulli variables.
4.1.8. Mixture of multivariate Bernoulli, with dependence. We also fit a two-component multivariate Bernoulli mixture that accounts for within-component correlations among the annotations. Since we only have k = 4 binary annotations there are only 2 k possible functional annotation vectors. Let these vectors be X j for 1 ≤ j ≤ 2 k , and X be the 2 k × k matrix of these annotation vectors. Let B j be the number among the m variants whose values of the functional annotations is X j , and let B = (B 1 , . . . , B 2 k ).
To initialize our EM algorithm that accounts for within-component correlations, we use a twocomponent multivariate binary mixture model that assumes conditional independence of the annotations within each component. Fitting this mixture model yields the mixing coefficient π 1 for the first component (the mixing coefficient for the second component is 1 − π 1 ) as well as, for each possible vector of functional annotation values X j with 1 ≤ j ≤ 2 k , the posterior probability p j1 that a variant with this vector of functional annotations is in the first component. Let p 1 = (p 11 , . . . , p 2 k 1 ), and p 2 = 1 − p 1 . Using these mixing coefficients and posterior probabilities, we use the following EM algorithm to fit our model:
Step 1. Calculate the expected number of variants assigned to the two components using the current estimates of the posterior probabilities. Let C 1 = (B 1 p 11 , . . . , B 2 k p 2 k 1 ) be the vector of number of variants assigned to the first component, and C 2 = (B 1 p 12 , . . . , B 2 k p 2 k 2 ) be the vector of the number of variants assigned to the second component.
Step 2. Fit two log-linear models, using the vectors C 1 and C 2 (rounded, so that we can use a Poisson response distribution) as weights. The design matrix for each of these two models consists of the matrix X to which columns consisting of products of appropriate columns of X are adjoined (see discussion on interaction terms below). These products induce withincomponent dependence between the functional annotations. Let D 1 and D 2 be the fitted values resulting from fitting these log-linear models.
Step 3. Reestimate the posterior probabilities with the equations
and p j2 = 1 − p j1 .
Step 4. Reestimate the mixing coefficients π 1 and π 2 with the equations:
Repeat steps 1 through 4 until convergence.
We wish to account for the most important within-component correlations between the different functional annotations. In our applications below, we use four different functional annotations, so there are six different pairs of annotations whose correlation we could model (we do not model higher-order correlations between annotations). To avoid overfitting, we pick two correlations for each component. In our application, where we use the annotations H3K4me1, H3K4me3, H3K9ac and H3K27ac, we include interaction terms between H3K9ac and H3K4me3 and H3K9ac and H3K27ac, since these pairs have the highest marginal correlations, as illustrated by Supplemental Figure S1 .
4.2.
Generalized Jaccard index of overlap. If X = (x 1 , . . . , x k ) and Y = (y 1 , . . . , y k ) are two vectors with x i , y i ≥ 0 (e.g. vector of posterior probabilities for variants to be in the functional components for two different tissues), then the generalized Jaccard index of overlap is defined as:
When X and Y are binary vectors, then the Jaccard index of overlap is simply the size of the intersection divided by the size of the union of the two sets. The closer it is to 1, the more overlap there is between the two sets. A Jaccard index of 0 means no overlap.
4.3.
Promoter and tissue-specific enhancer regions. The promoter region of a protein-coding gene is defined as the union of the regions 2,500 bases upstream of any protein-coding transcripts for the gene, as defined by GENCODE version 24. For enhancer regions we use SNPs within any enhancer region, with respect to any tissue.
4.4.
GTEx enrichment. Let G 1 , . . . , G 44 be the 44 GTEx tissues with at least 70 samples (Supplemental Table S3 ), and R 1 , . . . , R 127 be the 127 Roadmap tissues. For a given tissue in GTEx G i we are interested in identifying the Roadmap tissue R j with the highest enrichment in eQTLs from G i relative to other tissues in GTEx. Let
Note that the number of eQTLs in tissue G i is a weighted count, with an eQTL weighted by the inverse of the number of GTEx tissues in which the variant is eQTL. This way eQTLs that are unique to tissue G i are given higher weight relative to eQTLs that are shared across many tissues. We cannot use p R j | G i to rank Roadmap tissues because of the different sizes of the functional component for the Roadmap tissues. Instead we need to normalize p R j | G i as follows:
The eQTLS that we used in these analyses are all significantly associated SNP-gene pairs in each of these 44 GTEx tissues, produced using a permutation threshold-based approach as described by the GTEx Consortium [17].
4.5. Gene-based tests using tissue specific functional SNPs and enhancers-target genes maps. For each gene G and trait D we want to test H 0 : G is independent of D. We assign SNPs to genes annotated as protein-coding genes in GENCODE version 24. A SNP is assigned to a gene with respect to a particular tissue if 1) it is in the region from the first to the last exon for the gene, as delineated by GENCODE (region 1), 2) if it is within the promoter region for the gene (defined as the union of the regions 2,500 bases upstream of any protein-coding transcripts for the gene, as defined by GENCODE) (region 2), 3) if it is within an enhancer region assigned to the gene with respect to that particular tissue [12] (region 3) or 4) if it is within 200,000 bases of the gene and not within regions 1, 2 or 3 with respect to any other gene. We consider a SNP to be functional in the context of a trait D if the posterior probability for the SNP to be functional in the top tissue (i.e., the tissue with the highest Z score in the LD score regression for that trait) for the trait D is greater than 0.5. For each of these functional SNPs we have a Z score statistic from the association test of the SNP and trait D in a GWAS study. Let Z i be the Z score for the ith SNP connected to gene G.
Let A be a latent variable, with A = 1 if G is associated with D and 0 otherwise. For each SNP i we compute a Bayes factor (BF):
Then for a gene G the log(BF) can be approximated by the average log(BF) for the SNPs connected to G. We now show how we can compute the BF for a given SNP. We follow closely the approach in He et al. [58] .
Let V i be a second latent variable such that V i = 1 if SNP i is associated with trait D and 0 otherwise. Then we have:
We take P (V i = 1|A = 0) = 0, as we assume that if a gene is not associated with a trait then no SNP connected to the gene is associated with the trait. We also take P (V i = 1|A = 1) = 0.8, reflecting the high probability that a functional SNP in a trait associated gene is likely to be associated with the trait. When V i = 0 then Z i ∼ N (0, 1). Let us now consider the case V i = 1. For a quantitative trait, if the Z score comes from a linear regression of trait on genotype, He et al. [58] show, assuming Hardy-Weinberg equilibrium, that when V i = 1,
where M is the sample size and p is the SNP population allele frequency. Following He et al. [58] , we take σ a = 0.5, based on earlier Bayesian studies for quantitative traits [59] .
For a binary trait, assuming the Armitage trend statistic was used to derive the Z scores, He et al. [58] show that:
where β is the effect size (the logarithm of the odds ratio of the risk allele), σ 2 a is the prior variance of the effect size for functional SNPs and µ 1 , σ 2 0 and σ 2 1 are defined below.
Based on prior studies, we take σ 2 a = 0.2 [59] . To calculate µ 1 , σ 2 0 and σ 2 1 we must estimate genotype frequencies among cases and controls; we do not know these since we only have summary statistics from the GWAS studies. Let the genotypes be indexed by i, i ∈ {0, 1, 2} and let x i be the number of high-risk alleles in genotype i. Let the frequency of the ith genotype in cases be p i and in controls q i . Also, let f i be the penetrance of the ith genotype, its probability of causing the trait, and g i its frequency in the population. Given any effect size β, the frequencies p i and q i can be estimated assuming Hardy-Weinberg equilibrium, the prevalence of the trait K, the population allele frequency for the high-risk allele p and the multiplicative genetic model. Specifically, we have the following equations that can be used to derive p i and q i , under a multiplicative model for the penetrances, where γ = e β :
and the following equations for µ 1 , σ 2 1 and σ 2 0 :
where φ is the proportion of cases in the GWAS sample. The prevalences we assume for the binary traits are in Supplemental Table S5 . Comparison of five different methods. Supplemental Figure S4 shows various features of the Eigen-PC and four different mixture models discussed in the Methods section, fit using these four annotations in the 127 cell types. The top left panel shows the weights in the 127 tissuespecific Eigen-PC models for each of the 4 histone modification marks. The weights are quite consistent across tissues, and are highest for H3K9ac, the annotation most highly correlated with the others, and lowest for H3K4me1, the annotation least correlated with the others. For the four non-functional components are much less separated in the npEM-binned models than they are in the other three models. The bottom right panel shows the distribution of pairwise correlations between the functional scores for the reference SNPs for the five different functional scores (posterior probabilities, in the case of the mixture models) across the different cell types. The binary methods and the npEM-quantile method give highly correlated posterior probabilities; the Eigen-PC score is less highly correlated with those three methods. The posterior probabilities from the npEM-binned method have low to modest correlation with the scores from the other methods. Overall, npEMbinned tends to perform poorly. We speculate that this is because there are technical artefacts, like chromatin accessibility, that cause weak correlations between histone modification measurements that are not related to function, in the range close to zero. With the regular binning used for the npEM-binned method, variants in this range close to zero represent most of the variants in the training set (see Figure S1 ) and so the npEM-binned mixture models largely reflect these artefactual correlations. On the other hand, with the binning procedure we use for the npEM-quantile method, functional variants with high histone modification measurements are enriched, and so the mixture models reflect the correlations caused by functional status reflected in these high modification measurements.
In Supplemental Figure S5 we show a multidimensional-scaling visualization of the correlations between the functional scores for a set of reference SNPs for 127 different tissues for the five methods. As shown, the two binary models, Eigen-PC and npEM produce similar patterns of correlations, while npEM-binned does not seem to perform well in separating the different types of tissues (see also Supplemental Figure S6 showing correlations for the primary cells and primary tissues, along with their embryonic tissue of origin).
We have performed LD score regression by using functional scores derived from the four methods (we have excluded npEM-binned as it performs poorly in the analyses above). In Supplemental Figure S7 we show the top tissue for 21 complex traits using functional scores derived using each of the four methods, as well as the four individual histone marks. Overall, we find that npEM-quantile performs well and identifies plausible candidate tissues for most of the complex traits we analyzed. Although one can analyze the individual histone marks, the results can be difficult to interpret as different histone marks can implicate different tissues. For example, for "T2Diabetes", pancreas is the top tissue only for npEM-quantile, mvB and H3K9ac; the other three histone marks identify different tissues as the top tissue.
LD score regression to identify the tissue of interest. The LD score regression approach [18] uses two sets of SNPs, reference SNPs and regression SNPs. The regression SNPs are SNPs that are used in a regression of χ 2 statistics from GWAS studies against the "LD scores" of those regression SNPs. The LD score of a regression SNP is a numeric score which captures the functional effects of all reference SNPs in LD with that SNP, appropriately weighted to account for the extent of the LD. Here, following [18] we use as regression SNPs HapMap3 SNPs, chosen for their high imputation quality, and as reference SNPs those SNPs with minor allele count greater than 5 in the 379 European samples from the 1000 Genome Project [15] . We first compute tissue-specific scores using each of our methods for the 9, 254, 335 SNPs with minor allele count greater than 5 in the 379 European samples from the 1000 Genomes Project, which we will subsequently use as our "reference SNPs" for LD score regression.
In the LD score regression approach, a linear model is used to model a quantitative phenotype y i for an individual i:
Here G is some set of SNPs, X ij is the genotype of individual i at SNP j, and β j is the effect size of SNP j. In this framework, β, the vector of all the β j , is modeled as a mean-0 random vector with independent entries, and the variance of β j depends on the functional categories included in the model. We have a set of functional categories C 1 , . . . , C C , and the variance of a SNP's effect size will depend on which functional categories it belongs to:
Here τ c is the contribution of SNPs in category C c to the variance of effect sizes of SNPs in that category. In [18] , the authors show that τ c can be estimated through the following equation:
Here χ 2 j is the chi-squared statistic for SNP j from a GWAS study, N is the sample size from that study, and l(j, c) is the LD score of SNP j with respect to category c, l(j, c) = k∈Cc r 2 jk . Here r 2 jk is the correlation between SNP j and a SNP k in category C c , so that the sum in the above equation is over categories, with τ c weighted by the sum of correlations between SNP j and all SNPs in category C c . This equation therefore allows for the estimation of the τ c via the regression of the chi-squared statistics from a GWAS study on the LD scores of the regression SNPs.
Here, we extend the LD score by allowing SNPs to be assigned to a category C c probabilistically, that is, we assume a probability p kc that SNP k belongs to category C c , and therefore that the variance of its effect size is affected by its membership in that category. This only involves minor changes to the above equations, namely, we have that
where p jc is the probability that SNP j belongs to category C c , and as above
although now l(j, c) = k∈Cc p kc r 2 jk , p kc being the probability that SNP k belongs to category C c . We can therefore still estimate the τ c via the regression of the chi-squared statistics from a GWAS study on the LD scores of the regression SNPs, but in calculating these LD scores we weight the correlation of a SNP k with a regression SNP j by the probability that SNP k belongs to a particular category.
For each tissue and phenotype, and each of our functional scores, we fit a separate LD score regression model, including the LD score derived using the posterior probability each regression SNP is in the functional component in that tissue, to estimate the contribution of that component to the variability of effect sizes of SNPs that belong to that component. To control for overlap of the tissue-specific functional score with other functional categories, we use the same 54 baseline categories used in [18] , which represent various non-tissue-specific annotations, including histone modification measurements combined across tissues, measurements of open chromatin, and super enhancers.
Note that for the Eigen-PC approach, the derivation above does not strictly apply, but we still interpret the coefficient τ estimated in the LD score regression as the contribution of the component represented by the Eigen-PC approach to the variability of effect sizes of SNPs in that category. 
